Description: Avicanna Inc. focuses on the research and development, cultivation, manufacture, and commercialization of plant-derived cannabinoid-based products and extracts in North America, Latin America, Europe, and Asia. It intends to offer plant-derived cannabinoid pharmaceuticals, phyto-therapeutics, derma-cosmetics, and extracts. The company was founded in 2016 and is headquartered in Toronto, Canada.
Home Page: www.avicanna.com
480 University Avenue
Toronto,
ON
M5G 1V2
Canada
Phone:
647 243 5283
Officers
| Name | Title |
|---|---|
| Mr. Aras Azadian B.Econ, Mba | Co-Founder, CEO & Director |
| Mr. Phillip Cardella C.A., CPA | Chief Financial Officer |
| Ms. Ivana Maric | Executive Vice President of Marketing |
| Mr. Stephen Kim | Chief Legal Officer & General Counsel of Avicanna USA Inc. |
| Dr. Karolina Urban | Executive Vice President of Scientific & Medical Affairs |
| Mr. Arash Moghani MBA | Executive Vice President of Operations & Technology |
| Ms. Ingrid Diaz | VP, Assistant General Counsel & Corporate Compliance Officer |
| Mr. Enric Pujol | Vice President of People |
| Dr. Carlos Enrique Maldonado Muete | SVP of Clinical Development |
Exchange: OTCQX
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 25.5231 |
| Price-to-Sales TTM: | 1.5305 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 87 |